Skip to main content

Table 3 The association between quintile of annually change in serum urate and all-cause and cause-specific mortality

From: Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up

 

Q1

Q2

Q3

Q4

Q5

All-cause mortality

 Population no. (cases)

21,556 (1465)

21,603 (747)

21,494 (574)

21,548 (579)

21,550 (889)

 Incidence rate, per 1000 person-years

8.23

4.01

3.06

3.13

5.16

 Age- and sex-adjusted HR*

2.18 (1.98–2.41)

1.19 (1.07–1.33)

1 (ref)

1.10 (0.98–1.23)

1.92 (1.73–2.13)

 Multiple adjusted HR*

2.14 (1.93–2.37)

1.20 (1.07–1.33)

1 (ref)

1.05 (0.93–1.17)

1.66 (1.49–1.84)

 In 107,743 men HR*

2.15 (1.93–2.39)

1.20 (1.07–1.34)

1 (ref)

1.03 (0.91–1.16)

1.64 (1.47–1.83)

 In 23,168 women HR*

2.16 (1.51–3.09)

1.21 (0.82–1.78)

1 (ref)

1.28 (0.87–1.88)

1.81 (1.26–2.61)

Cardiovascular mortality

 Population no. (cases)

21,556 (344)

21,603 (189)

21,494 (141)

21,548 (144)

21,550 (216)

 Incidence rate, per 1000 person-years

1.93

1.01

0.75

0.78

1.25

Multiple adjusted HR*

2.20 (0.93–5.22)

2.53 (1.11–5.74)

1 (ref)

1.90 (0.78–4.62)

2.49 (1.03–6.01)

 In 107,743 men HR*

1.80 (1.45–2.24)

1.23 (0.98–1.55)

1 (ref)

1.06 (0.83–1.35)

1.71 (1.36–2.15)

 In 23,168 women HR*

1.52 (0.79–2.94)

0.96 (0.48–1.94)

1 (ref)

0.87 (0.42–1.83)

0.68 (0.31–1.51)

Cancer mortality

 Population no. (cases)

21,556 (356)

21,603 (176)

21,494 (147)

21,548 (136)

21,550 (208)

 Incidence rate, per 1000 person-years

2.00

0.94

0.78

0.73

1.21

 Multiple adjusted HR*

2.37 (1.93–2.90)

1.15 (0.92–1.43)

1 (ref)

0.97 (0.77–1.22)

1.57 (1.26–1.94)

 In 107,743 men HR*

2.46 (1.99–3.04)

1.20 (0.96–1.51)

1 (ref)

0.93 (0.72–1.19)

1.48 (1.18–1.86)

 In 23,168 women HR*

1.72 (0.86–3.47)

0.68 (0.29–1.57)

1 (ref)

1.43 (0.71–2.90)

2.65 (1.37–5.11)

Other mortality

 Population no. (cases)

21,556 (330)

21,603 (161)

21,494 (122)

21,548 (118)

21,550 (162)

 Incidence rate, per 1000 person-years

1.85

0.86

0.65

0.64

0.94

 Multiple adjusted HR*

2.34 (1.88–2.91)

1.21 (0.96–1.53)

1 (ref)

1.00 (0.78–1.29)

1.43 (1.12–1.81)

 In 107,743 men HR*

2.22 (1.77–2.78)

1.11 (0.87–1.41)

1 (ref)

0.91 (0.70–1.18)

1.33 (1.04–1.70)

 In 23,168 women HR*

6.98 (2.35–20.7)

4.94 (1.66–14.7)

1 (ref)

3.93 (1.28–12.0)

4.35 (1.42–13.3)

  1. *Model adjusted for age (years); sex; baseline serum urate (mmol/L); smoke status (current, past, or never); alcohol consumption status (current, past, or never); physical activity (never, sometimes, or active); average monthly income of each family member (< 500, 500–2999, or ≥ 3000¥); education (illiteracy/elementary school, middle school, or college/university); sodium intake (< 6.0, 6.0–9.9, or ≥ 10.0 g/day); father and mother’s cardiovascular disease history (yes or no); use of aspirin, antihypertensive, hypoglycemic, and lipid-lowering agents (yes/no for each); systolic blood pressure (quintile); diastolic blood pressure (quintile); fasting blood glucose (< 4.0, 4.0–5.5, 5.6–6.9, or ≥ 7 mmol/L); triglycerides (< 1.7, 1.7–2.2, 2.3–5.5, or ≥ 5.6 mmol/L); low-density lipoprotein cholesterol(< 1.80, 1.80–3.33, 3.34–4.91, or ≥ 4.92 mmol/L); body mass index (< 25.0, 25.0–29.9, or 30 kg/m2); high sensitive C-reactive protein (< 1, 1–2.9, or ≥ 3 mg/L), and estimated glomerular filtration rate (< 30, 30–59, 60–89, or ≥ 90 mL/min/1.73 m2)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us